Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug ResistanceChayanika Biswas *1, Sharon C-A. Chen *1,2,3, Catriona Halliday 1,2, Elena Martinez 1, Rebecca J. Rockett 1, Qinning Wang 1, Verlaine J. Timms 1, Rajat Dhakal 1, Rosemarie Sadsad 1, Karina J. Kennedy 4, Geoffrey Playford 4,5, Deborah J. Marriott 6, Monica A. Slavin 7, Tania C. Sorrell 1,3, Vitali Sintchenko 1,2,3
1Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, 2Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR, 3Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, 4Department of Microbiology and Infectious Diseases, Canberra Hospital and Health Services, Australian National University Medical School, 5Infection Management Services, Australian National University Medical School, 6Department of Microbiology and Infectious Diseases, St. Vincent's Hospital, 7Department of Infectious Diseases, Peter MacCallum Cancer Centre
This study implemented whole genome sequencing for analysis of mutations in genes conferring antifungal drug resistance in Candida glabrata. C. glabrata isolates resistant to echinocandins, azoles and 5-flucytosine, were sequenced to illustrate the methodology. Susceptibility profiles of the isolates correlated with presence or absence of specific mutation patterns in genes.
